Memantine

Memantine

SCHEMBL2545234

CC12CC3CC(C)(C1)CC(N)(C3)C2.CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B

The experimentally established mechanism targets of Memantine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 known ✓ Q05586 10/20 1.00
GRIN2A known ✓ Q12879 10/20 1.00
GRIN2D known ✓ O15399 9/20 0.95
GRIN3B known ✓ O60391 9/20 0.95
GRIN2B known ✓ Q13224 9/20 0.95
GRIN2C known ✓ Q14957 9/20 0.95
GRIN3A known ✓ Q8TCU5 9/20 0.95
LMNA P02545 4/20 1.00
PMP22 Q01453 2/20 1.00
NPSR1 Q6W5P4 1/20 1.00
SLC22A1 O15245 2/20 0.95
NFKB1 P19838 2/20 0.95
HTT P42858 2/20 0.95
ESR1 P03372 1/20 0.95
ADRB3 P13945 1/20 0.95
ACHE P22303 1/20 0.95
OPRK1 P41145 1/20 0.95
MTOR P42345 1/20 0.95
CYP1A2 P05177 1/20 0.95
CYP2D6 P10635 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Memantine SCHEMBL27711131 1.00 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL3053 1.00 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL31328273 1.00 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL6368832 1.00 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL5011429 0.98 GRIN1 (0.95) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL28416563 0.98 GRIN1 (0.95) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL23327176 0.97 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL8126868 0.97 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL2688 0.97 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1
Memantine SCHEMBL2689 0.97 GRIN1 (1.00) GRIN1GRIN2ALMNAPMP22NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150328147-A1 METHOD FOR INTRODUCING BIOLOGICALLY ACTIVE SUBSTANCES INTO THE BRAIN BBU-VITA CORP. (VG) 2015-11-19 US claimed
CN-112494509-A Composition for preventing and treating Alzheimer's disease and application thereof 南京生命原健康科技有限公司 2021-03-16 CN disclosed
CN-103800306-B Memantine oral membrane and preparation method thereof 重庆医药工业研究院有限责任公司 2020-06-19 CN disclosed
EP-3156064-B1 APPLICATION OF YB-1 PROTEIN AND FRAGMENTS THEREOF FOR PREPARING MEDICINAL AGENTS IN TREATING ALZHEIMER'S DISEASE INSTITUTE OF PROTEIN RES RUSSIAN ACADEMY OF SCIENCES (RU) 2019-11-20 EP disclosed
US-10143722-B2 Application of YB-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease DUPONT, MARIA (DE) 2018-12-04 US disclosed
EP-3156064-A2 APPLICATION OF YB-1 PROTEIN AND FRAGMENTS THEREOF FOR PREPARING MEDICINAL AGENTS IN TREATING ALZHEIMER'S DISEASE Institute Of Protein Research Russian Academy Of Sciences (RU) 2017-04-19 EP disclosed
US-20170095435-A1 AGENT FOR THE TREATMENT AND PREVENTION OF AUTISM SPECTRUM DISORDERS ZAO ALMAZ PHARM (RU) 2017-04-06 US disclosed
EP-3150231-A1 AGENT FOR THE TREATMENT AND PREVENTION OF AUTISM SPECTRUM DISORDERS ZAO "ALMAZ PHARM" (RU) 2017-04-05 EP disclosed
US-20160331806-A1 APPLICATION OF YB-1 PROTEIN AND FRAGMENTS THEREOF FOR PREPARING MEDICINAL AGENTS IN TREATING ALZHEIMER'S DISEASE DUPONT, MARIA (DE) 2016-11-17 US disclosed
US-9101451-B2 Method for correcting pathological configurations of segments of the lower extremities and device for realizing same Zakrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvenny Tsentr “Ogonek” (RU) 2015-08-11 US disclosed
US-6255348-B1 AIDS THERAPY MERZ + CO. GMBH & CO. (DE) 2001-07-03 US disclosed
US-6172116-B1 NEUTROPHIL ACTIVATION; TREATING AUTOIMMUNE DISEASES MERZ + CO. GMBH & CO. (DE) 2001-01-09 US disclosed
US-6066652-A Method for treating diseases of the inner ear using adamantane derivatives TINNITUS FORSCHUNGS-UND ENTWICKLUNGS GMBH (DE) 2000-05-23 US disclosed
CN-1224366-A Pharmaceutical administration form MUELLER D (DE) 1999-07-28 CN disclosed
CN-1194581-A Use of adamantan derivatives for treating diseases of inner ear TIANLITUS RESEARCH AND DEV CO (DE) 1998-09-30 CN disclosed
EP-0845984-A1 USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS MERZ + CO. GmbH & Co. (DE) 1998-06-10 EP disclosed
EP-0834310-A1 Use of adamantin-derivatives for the treatment of internal-ear-diseases Zenner, Hans Peter, Prof. Dr. med. (DE) 1998-04-08 EP disclosed
EP-0759295-B1 Use of adamantan derivatives for the treatment of tinnitus ZENNER HANS PETER PROF DR MED (DE) 1998-03-04 EP disclosed
WO-1997007791-A1 USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS MERZ + CO. GMBH & CO. (DE) 1997-03-06 WO disclosed
EP-0759295-A1 Use of adamantan derivatives for the treatment of internal ear diseases Zenner, Hans Peter, Prof. Dr. med. (DE) 1997-02-26 EP disclosed